Search

Search Constraints

You searched for: Author/Creator Topp, Max S.

Search Results

1. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis. (18th March 2021)

2. Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies. Issue 14 (3rd May 2016)

3. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Issue 9 (29th July 2019)

4. Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs. Issue 6 (11th August 2015)

5. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Issue 11 (18th September 2020)

6. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma. (29th September 2021)

8. Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Issue 4 (3rd November 2020)

9. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Issue 3 (23rd December 2017)

10. Phase II study of fixed‐duration single‐agent ibrutinib in relapsed nodular lymphocyte‐predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Issue 4 (24th March 2022)